|
Testimonials
Commenting on the Study, Lead Investigator, Clyde W. Yancy, M.D., Associate Professor of Internal Medicine/Cardiology of UT Southwestern Medical Center at Dallas, stated, "The Study's results demonstrate the BioZ's accuracy in measuring cardiac output and, in fact, when compared to the gold standard, Fick, has the same degree of accuracy as thermodilution. This valuable technology is a viable alternative to the invasive procedures currently used and could potentially have a significant impact in the future treatment of heart failure."2 Commenting on the study, David Milzman, M.D., FACEP, Director of Research Division, at Providence Hospital, Washington, D.C., stated, "Utility of the BioZ's technology improves patient care, clinical outcomes, and hospital charges in the emergency room. Similar to blood pressure and oxygen saturation, I envision ICG technology becoming a standard of care."3 Commenting on the study, Hector Ventura, M.D., Co-Director, Advanced Heart Failure and Cardiac Transplant Center, Tulane University Medical Center, New Orleans, stated, "Patients with advanced heart failure require complex medical decisions about care during routine clinical visits. Up to now, most of these decisions have been based primarily on routine history and physical examination. In addition to traditional methods, our study utilized the BioZ's ICG technology as an adjunctive tool to history and examination and demonstrated that patients with low Cardiac Indexes and normal Thoracic Fluid Contents were more likely to be hospitalized for decompensation within one month after the clinic visit. We are encouraged that the BioZ's noninvasive ICG now provides us with hemodynamic data important in assessing and directing the treatment of advanced heart failure patients, and its potential to improve outcomes and decrease healthcare costs."4 Commenting on the study, Dr. Mary Anne Papp, Director, Heart Failure Program at Michael Reese Hospital, stated, "The BioZ's noninvasive ICG measurements reduce and can virtually eliminate the need for an invasive PAC measurement and are invaluable in patients undergoing inotropic infusion therapy. The study highlights the importance of ICG data in optimizing patient care, which translates into improved patient functional status, decreased emergency room visits, and reduced hospitalizations during short and long term follow-up (previously published data). ICG technology is fast becoming a necessity in treating heart failure patients."5 David P. Milzman, M.D., FACEP, Director of Research Division, at Providence Hospital, Washington, D.C., commenting on his studies, stated, "Use of the PAC in the Emergency Department is impractical at best and not a viable monitoring option. The noninvasive BioZ Systems allow emergency physicians to more accurately and effectively treat heart failure patients and provide real-time feedback on the effects of therapeutic intervention. This improved initial treatment results in a reduction of hospital stay and associated costs and improvement in patient care and survival. This noninvasive method to obtain hemodynamic data is revolutionary and an important advancement in the care of heart failure patients in the Emergency Department."6 Daniel W. Ziegler, M.D., F.C.C.P., F.A.C.S., Chief Investigator of the Studies, stated, "In view of the potential life-threatening complications and high costs associated with the PAC, we are excited to discover a noninvasive alternative that can accurately monitor cardiac output, stroke volume, and systemic vascular resistance. The BioZ has proven to be a safe and cost-effective alternative for providing the vital information that we need in assessing and directing treatment of critically ill patients."6 John E. Strobeck, M.D., Ph.D., Director of the Heart-Lung Associates of America, stated, "In our clinic, the use of monitoring with ICG has become a standard of care. For over three years, we have used this vital data to assist our physicians and nurses to fine-tune the pharmacologic and fluid management of hypertensive patients and those with heart failure. This new 'informed' approach to treatment is key in improving outcomes for the millions affected by high blood pressure, heart failure, and other cardiovascular diseases."7, 1CardioDynamics
Announces Study Demonstrating Dramatic Results - Presented At
Fifth Annual Heart Failure Society Meeting, San Diego, CA,
Sept. 18, 2001 / PRNewswire -CardioDynamics
|